| Registro completo |
| Provedor de dados: |
BJMBR
|
| País: |
Brazil
|
| Título: |
Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
|
| Autores: |
Oliveira,G.A.P.
Costa,E.S.
Freitas,M.S.
Dutra,F.F.
Maia,S.F.
Guerra,M.C.
Tabernero,M.D.
Borojevic,R.
Otazu,I.B.
Silva,J.L.
|
| Data: |
2010-06-01
|
| Ano: |
2010
|
| Palavras-chave: |
Chronic myeloid leukemia
Imatinib mesylate
Minimal residual disease
Children
|
| Resumo: |
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.
|
| Tipo: |
Info:eu-repo/semantics/report
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009
|
| Editor: |
Associação Brasileira de Divulgação Científica
|
| Relação: |
10.1590/S0100-879X2010007500026
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Medical and Biological Research v.43 n.6 2010
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
